Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

Completed · Phase 2

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Pegylated arginine deiminase may stop the growth of tumor cells by taking away an amino acid needed for cell growth. PURPOSE: This phase II trial is studying how well pegylated arginine deiminase works in treating patients with metastatic melanoma that cannot be removed by surgery.

Key facts

Study ID

NCT00450372

Run by

University of Miami

People needed

38

Starts

2004-06-01

Expected to finish

2012-02-01

Last updated by the study team

2017-02-08

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Miami Sylvester Comprehensive Cancer Center - Miami — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.